While the oral and late-breaking Esmo abstracts are under wraps until next week, the unveiling of the meeting’s poster presentations has given investors a few more showdowns to look forward to, including those between Clovis, Medivation, Astrazeneca and Tesaro’s Parp inhibitors.
The top places at the meeting’s late-breakers have also been confirmed, though bizarrely one of the most important studies, Bristol-Myers Squibb’s failed Checkmate-026, has been edged out of the press programme by Oncogenex’s failed Affinity trial. While two of Opdivo’s checkpoint inhibitor competitors, Merck & Co’s Keytruda and Roche’s Tecentriq, star in their own NSCLC late-breakers.
The articles gathered here highlight recent breakthroughs and setbacks and flag the approaching data points.
Bristol's Opdivo fall-out brings others into play
Puma files, and the battle begins
Clovis fights back into crowded Parp race
